Spring Event 2023
Valorization.
From Scientist to Entrepreneur;
How to commercialize your research
Don’t miss out on the upcoming Young@Heart Spring Event on March 31, highlighting the importance of valorization in science to learn how to commercialize your research! Expect to hear and learn from personal experiences in start-up processes, a masterclass on entrepreneurship and different workshops aimed at developing your skills on this interesting subject!
Location: “De Driehoek”, Utrecht (near Utrecht Central Station)
09.30 – 10.05 | Registration and Introduction |
10.05 – 10.30 | N. Tuysuz from TTO Erasmus MC |
10.30 – 11.55 | Success stories | PHLOX, VARMX, and R. de Ree (DCVA) |
11.55 – 13.00 | Lunch break |
13.00 – 13.10 | Energizer |
13.10 – 14.10 | Masterclass by T. de Kraker (NovelT & UT) |
14.10 – 14.20 | Break |
14.20 – 15.40 | Workshops | V. de Lusenet & N. Ilahibaks (AMC) |
15.40 – 16.30 | Challenges of entrepreneurship | S. Hermans (Health Holland) & C. Maas (UMCU) |
16.30 | Closing remarks & drinks |
Speaker information
Vincent de Lusenet
Vincent is a freelance coach who is specialized in the development of leadership, communication, and teambuilding. Creativity, energy, connection and dynamics are important key elements in his workshops. During this event he will give a workshop on how to pitch your research ideas and bring it to the market.
Tim de Kraker
Tim is an experienced entrepreneur, now active at the Knowledge transfer office of the University of Twente. In the past 10 years, over 400 researchers have followed his Entrepreneurial Researcher Program and over 100 deals of knowledge transfers have been signed. Would you like to learn more on how to bring your research to the market? Join this masterclass.
Rob de Ree
Rob is Chair of valorization at the Dutch Cardiovascular Alliance (DCVA), co-manager along RegMed XB of FIRST, a joint early phase investment fund. Currently, Rob is operating partner at Biogeneration Ventures since 2016, serving on the board and in interim management positions in the fund’s portfolio companies. In addition, he is CEO of NorthSea Therapeutics and serves on the board of Mellon Medical.
Simone Hermans
Simone has worked for several pharmaceutical companies, big and small and in different roles. She went from production to sales and later on worked in a start-up like environment where she contributed to bringing a drug to the European market. Currently she coordinates different activities at LifeSciences@Work (Health-Holland) to stimulate innovation within Life Sciences and Health sector.”
Coen Maas
Coen is an expert in thrombosis and hemostasis and associate professor at University Medical Centre Utrecht. Coen studies multiple rare, hematological diseases, is (co)author of >100 scientific publications and has been invited for >45 scientific presentations. Coen is inventor of two patents and the co-founder and Scientific Advisor of the spin-off TargED, founded in 2020 at University Medical Centre Utrecht.
Nesrin Tuysuz
Since 2021 Nesrin has been working as a business developer at Luris in the LUMC. Their focus is to transfer patents and licenses of novel technology as partnering opportunities. She helps bringing inventions and new developments from universities to the general public by assisting in the negotiations with interested parties.
Presented company information
PHLOX
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Their ultimate goal is to cure genetic heart disease and they want to develop a new class of potent precision genetic medicines. – Adapted from: https://www.phloxtherapeutics.com
VARMX
VarmX aims to develop and manufacture therapeutic proteins to restore hemostasis in bleeding patients. Their lead product called ‘VMX-C001’ is a potential safe and effective reversal agent for prevention and treatment of bleeding in presence of factor Xa inhibitors. Their goal is to bring this potential best-in-class reversal agent to the clinic. – Adapted from: https://www.varmx.com